Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 9/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 7/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23528276 | 0.89 | MET (0.43) | METMEN1KMT2APDE4APDE4B | |
| SCHEMBL26527929 | 0.88 | GRIN2B (0.44) | METMEN1KMT2APDE4APDE4B | |
| SCHEMBL29569798 | 0.86 | GRIN2B (0.50) | METMEN1KMT2AGRIN1GRIN2B | |
| SCHEMBL23528379 | 0.86 | GRIN2B (0.50) | METMEN1KMT2AGRIN1GRIN2B | |
| SCHEMBL23758346 | 0.85 | CYP1A2 (0.48) | METMEN1KMT2APDE4APDE4B | |
| SCHEMBL26529132 | 0.84 | GRIN2B (0.44) | METMEN1KMT2APDE4APDE4B | |
| SCHEMBL23528778 | 0.82 | MET (0.38) | METPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL26528240 | 0.82 | MET (0.43) | METMEN1KMT2APDE4APDE4B | |
| SCHEMBL23528325 | 0.82 | MET (0.44) | METMEN1KMT2APDE4APDE4B | |
| SCHEMBL29570027 | 0.81 | MET (0.42) | METMEN1KMT2APDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025879-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11873290-B2 | — | — | 2024-01-16 | — | — | US | disclosed |
| US-20230321091-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321091-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | IL6, MUSK, SMN1; SMN2 | MET 4319/4885MEN1 4467/4885KMT2A 3767/4885 |
| US-11873290-B2 | — | IL6, MUSK, IL6ST | MET 4344/4885MEN1 4771/4885KMT2A 4022/4885 |
| US-20240025879-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | IL6, IL1B, IL1A | MET 4212/4885MEN1 4368/4885KMT2A 4169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.